Female sex | 19 (90%) |
---|---|
Age (years)a | 39.4 ± 20.8 |
AIRD | |
SLE | 13 (59%) |
ANCA-associated Vasculitis | 4 (18.2%) |
RA | 2 (9%) |
Systemic sclerosis | 1 (4.5%) |
Overlap syndrome | 1 (4.5%) |
Anti-sintetase syndrome | 1 (4.5%) |
Diagnosis AIRDb Time (months) | 10.5 (0–276) |
Hospitalization causea | |
Activity + Infection | 11 (50%) |
Infection only | 8 (36.5%) |
Activity only | 3 (13.6%) |
AIRD treatment | |
Maximum dose of corticosteroids in hospital (mg/ day)a | 87.7 ± 52.5 |
Corticosteroids dose above 1 mg /kg/ daya | 19 (86.4%) |
Methylprednisolone Pulse Therapya | 11 (50%) |
Immunosuppressant medicationsa | 11 (50%) |
Site of CMV infectiona | |
Lung | 10 (45.4%) |
Cytopenia | 9 (40.9%) |
Gastrointestinal tract | 6 (27.3%) |
Hospitalization timea(days) | 41.9 ± 34.1 |
Hospitalization time until CMV-Ag be requesteda(days) | 11.5 ± 12 |
Time of symptoms until CMV-Ag be requesteda(days) | 7.8 ± 7.1 |
Time from the first positive CMV-Ag to specific treatment be starteda(days) | 3.3 ± 3.1 |
Number of positive CMV-Ag nuclei after specific treatment | |
With Ganciclovirb | 15 (1–500) |
No ganciclovirb | 7 (1–4) |
Co-Infectionsa | 16 (72.7%) |
Polymicrobial Infections | 5 (22.7%) |
CMV reactivation during hospitalization | 0 |
Prophylaxis after standard Ganciclovir treatment | 0 |